Developer docs
API playgroundTry for free, no card

Search company profiles

NetScientific PLC

Full company profile

uuid0039ixv

Namestring
NetScientific PLC
Company typeenum
Private
Founded yearint
2013
Descriptiontext

NetScientific PLC is a London-headquartered, publicly listed (LSE:NSCI) investment and commercialisation group founded in 2007. The company maintains an international portfolio of life science, sustainability, and technology companies and functions as a holding entity that both takes equity stakes in and commercialises innovations from its portfolio companies. It operates with 51-100 employees from the United Kingdom and serves portfolio companies, co-investors, and shareholders as its principal counterparties.

The group's business model is that of a listed venture/investment holding company rather than a traditional single-product operating business. Revenue mechanics are not transparently disclosed but are likely to encompass equity gains, licence and royalty income, and commercialisation services rendered to portfolio companies. The portfolio was actively expanded in 2020 through two acquisitions: EMV Capital (a venture capital entity acquired 2020-08-27) and ProAxsis (a life science biomarker asset acquired 2020-10-19), the latter of which broadened the life sciences footprint while the former added in-house capital deployment capability. Leadership comprises founder and CEO Farad Azima, alongside Dr Ilian Iliev (also listed as CEO, likely at portfolio-company level), CFO Stephen Crowe, executive director Edward Hooper, and non-executive director Stephen Smith.

The disclosed financial dataset is internally inconsistent — reported revenues in the multi-trillion dollar range and EBITDA losses of comparable magnitude are not credible for a 51-100 employee UK-listed investment group and should be treated as suspect / corrupted. The qualitative data therefore carries more weight: a small headcount, two recent portfolio acquisitions, public listing, and a multi-vertical portfolio positioning the group as a niche listed vehicle for life science, sustainability, and technology commercialisation.

Short descriptiontext

NetScientific PLC is a London-based, publicly listed investment and commercialisation group (LSE:NSCI) that holds an international portfolio of life science, sustainability, and technology companies, generating returns through equity stakes, licensing, and commercialisation services.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
life sciences investment, technology commercialisation, sustainability ventures, portfolio management, innovation funding
Industry1 code
PRIMARYFSANACAE
Financial Services / Fintech Growth Equity
NAICS code3 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Financial Vehicles52599
  • Management of Companies and Enterprises551
Product category
Life Sciences & Technology Investment
Social media profiles2 records
Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NetScientific PLC is an investment and commercialisation group that builds, funds, and supports an international portfolio of innovative companies operating in life sciences, sustainability, and technology. The group provides capital, strategic guidance, and operational support to help its portfolio companies move from early-stage development to commercial success. Through acquisitions and direct investments, NetScientific offers investors exposure to a diversified portfolio of growth-stage science and technology ventures.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Portfolio Investment in Life Sciences Companies
CategoryInvestment Management
2Portfolio Investment in Sustainability Companies
CategoryInvestment Management
3Portfolio Investment in Technology Companies
CategoryInvestment Management
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston- and London-headquartered commercialisation group building and investing in early-stage technology companies from university research; comparable operating model and stage focus.

TypeBroad incumbent
Description

European venture capital investor with listed exposure to growth-stage technology companies; larger and broader than NetScientific but a relevant public-market comp for listed VC exposure.

TypeEmerging player
Description

UK-based early-stage investor specialising in university spin-outs in deep tech and life sciences; narrower scale than NetScientific but directly overlapping investment thesis.

TypeDirect peer
Description

London-listed life sciences investment company backing development-stage therapeutics and related platforms; closely comparable listed-investment structure and sector focus.

TypeDirect peer
Description

UK-listed commercialisation and investment group backing university-derived life sciences and technology businesses; the closest like-for-like peer given shared London listing and deep-tech / life-sciences thesis.

TypeBroad incumbent
Description

UK fund manager with venture and growth strategies spanning health-tech, deep tech, and sustainability; broader product set but overlapping sector mandate.

TypeDirect peer
Description

UK-listed regional venture capital investor across life sciences, software, and deep tech; comparable listed-VC structure with similar multi-sector exposure.

TypeDirect peer
Description

London-listed investment company focused on founding and funding life sciences businesses; directly comparable in mandate, listed-vehicle structure, and life-sciences specialisation.

TypeRegional player
Description

Oxford University-linked investment and venture-building platform across life sciences, deep tech, and sustainability; directly comparable commercialisation mandate.

TypeRegional player
Description

Cambridge-focused growth investor in deep tech and life sciences; similar sector mandate with a more concentrated geographic focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment12 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NetScientific PLC

Life Sciences & Technology Investmentnetscientific.net

NetScientific PLC is a London-based, publicly listed investment and commercialisation group (LSE:NSCI) that holds an international portfolio of life science, sustainability, and technology companies, generating returns through equity stakes, licensing, and commercialisation services.

What NetScientific PLC does

NetScientific PLC is a London-headquartered, publicly listed (LSE:NSCI) investment and commercialisation group founded in 2007. The company maintains an international portfolio of life science, sustainability, and technology companies and functions as a holding entity that both takes equity stakes in and commercialises innovations from its portfolio companies. It operates with 51-100 employees from the United Kingdom and serves portfolio companies, co-investors, and shareholders as its principal counterparties.

The group's business model is that of a listed venture/investment holding company rather than a traditional single-product operating business. Revenue mechanics are not transparently disclosed but are likely to encompass equity gains, licence and royalty income, and commercialisation services rendered to portfolio companies. The portfolio was actively expanded in 2020 through two acquisitions: EMV Capital (a venture capital entity acquired 2020-08-27) and ProAxsis (a life science biomarker asset acquired 2020-10-19), the latter of which broadened the life sciences footprint while the former added in-house capital deployment capability. Leadership comprises founder and CEO Farad Azima, alongside Dr Ilian Iliev (also listed as CEO, likely at portfolio-company level), CFO Stephen Crowe, executive director Edward Hooper, and non-executive director Stephen Smith.

The disclosed financial dataset is internally inconsistent — reported revenues in the multi-trillion dollar range and EBITDA losses of comparable magnitude are not credible for a 51-100 employee UK-listed investment group and should be treated as suspect / corrupted. The qualitative data therefore carries more weight: a small headcount, two recent portfolio acquisitions, public listing, and a multi-vertical portfolio positioning the group as a niche listed vehicle for life science, sustainability, and technology commercialisation.

NetScientific PLC firmographics

Firmographics
Name
NetScientific PLC
Website
https://netscientific.net
Company type
Private
Founded year
2013
Headcount range
1–10 employees
Short description
NetScientific PLC is a London-based, publicly listed investment and commercialisation group (LSE:NSCI) that holds an international portfolio of life science, sustainability, and technology companies, generating returns through equity stakes, licensing, and commercialisation services.
Ownership category
akta.pro rank

NetScientific PLC industry classification

Industry
Product category
Life Sciences & Technology Investment
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (52599), Management of Companies and Enterprises (551)
akta.pro industry
PRIMARYFSANACAE
Financial Services / Fintech Growth Equity

Keywords

  • Life sciences investment
  • Technology commercialisation
  • Sustainability ventures
  • Portfolio management
  • Innovation funding

Where NetScientific PLC is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

NetScientific PLC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

NetScientific PLC product offering

Product offering

Core offering

NetScientific PLC is an investment and commercialisation group that builds, funds, and supports an international portfolio of innovative companies operating in life sciences, sustainability, and technology. The group provides capital, strategic guidance, and operational support to help its portfolio companies move from early-stage development to commercial success. Through acquisitions and direct investments, NetScientific offers investors exposure to a diversified portfolio of growth-stage science and technology ventures.

Differentiator

Problem solved

Functional benefit

Products and services

  • Portfolio Investment in Life Sciences Companies
  • Portfolio Investment in Sustainability Companies
  • Portfolio Investment in Technology Companies

Companies that use NetScientific PLC

Customer profile

Ideal customer profiles1 record

NetScientific PLC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

NetScientific PLC partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights4 records

NetScientific PLC competitors and assessment

Company assessment

Direct peers

  • Allied Minds plc: Boston- and London-headquartered commercialisation group building and investing in early-stage technology companies from university research; comparable operating model and stage focus.
  • Arix Bioscience: London-listed life sciences investment company backing development-stage therapeutics and related platforms; closely comparable listed-investment structure and sector focus.
  • IP Group plc: UK-listed commercialisation and investment group backing university-derived life sciences and technology businesses; the closest like-for-like peer given shared London listing and deep-tech / life-sciences thesis.
  • Mercia Asset Management PLC: UK-listed regional venture capital investor across life sciences, software, and deep tech; comparable listed-VC structure with similar multi-sector exposure.
  • Syncona Limited: London-listed investment company focused on founding and funding life sciences businesses; directly comparable in mandate, listed-vehicle structure, and life-sciences specialisation.

Broad incumbents

  • Molten Ventures plc: European venture capital investor with listed exposure to growth-stage technology companies; larger and broader than NetScientific but a relevant public-market comp for listed VC exposure.
  • Octopus Investments: UK fund manager with venture and growth strategies spanning health-tech, deep tech, and sustainability; broader product set but overlapping sector mandate.

Emerging players

  • Parkwalk Advisors: UK-based early-stage investor specialising in university spin-outs in deep tech and life sciences; narrower scale than NetScientific but directly overlapping investment thesis.

Regional players

  • Oxford Science Enterprises: Oxford University-linked investment and venture-building platform across life sciences, deep tech, and sustainability; directly comparable commercialisation mandate.
  • Cambridge Innovation Capital: Cambridge-focused growth investor in deep tech and life sciences; similar sector mandate with a more concentrated geographic focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

NetScientific PLC social profiles

Digital presence

NetScientific PLC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NetScientific PLC leadership team

Management profile

Number of profiles

Profiles5 records

NetScientific PLC funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NetScientific PLC M&A and investment

M&A and investment

M&A2 records

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NetScientific PLC

What does NetScientific PLC do?

NetScientific PLC is an investment and commercialisation group that builds, funds, and supports an international portfolio of innovative companies operating in life sciences, sustainability, and technology. The group provides capital, strategic guidance, and operational support to help its portfolio companies move from early-stage development to commercial success. Through acquisitions and direct investments, NetScientific offers investors exposure to a diversified portfolio of growth-stage science and technology ventures.

When was NetScientific PLC founded?

NetScientific PLC was founded in 2013. It employs 1 to 10 people.

Where is NetScientific PLC based?

NetScientific PLC is headquartered in London, United Kingdom, in the Europe region.

Who are NetScientific PLC's main competitors?

Direct peers on record are Allied Minds plc, Arix Bioscience, IP Group plc, Mercia Asset Management PLC and Syncona Limited. Broad incumbents are Molten Ventures plc and Octopus Investments. Parkwalk Advisors is listed as an emerging player. Regional players are Oxford Science Enterprises and Cambridge Innovation Capital.

Does NetScientific PLC have an API?

No public API is recorded for NetScientific PLC.

What industry is NetScientific PLC in?

NetScientific PLC's product category is Life Sciences & Technology Investment. Its primary akta.pro industry code is FSANACAE, Financial Services / Fintech Growth Equity. Its NAICS code is 525.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investors' ChronicleA technology sector bargainVentive, a heating and ventilation solutions company, secured a £0.9m funding round led by EMV Capital, with £0.32m from existing shareholders and £0.6m in convertible loan conversions. Netscientific's portfolio fair valuation of £36.4m is three times its market capitalisation of £12.2m, and EMV retains an 11% stake in Ventive.ProactiveinvestorsNetScientific portfolio company Ventive secures £900,000 investmentVentive, a portfolio company of NetScientific, secured £900,000 in new investment comprising equity from existing shareholders and converted convertible loans. The funds will support the design, testing, and factory build of modular heat pumps while enhancing marketing capacity for its ventilation products. This marks the first closing of a proposed £1 million to £1.5 million investment programme led by EMV Capital.ProactiveinvestorsNetScientific investee PDS Biotechnology making ‘excellent’ progress on cancer treatment, say WH Ireland analystsPDS Biotechnology completed a critical Type-B meeting with the FDA, paving the way for a pivotal study of a combination therapy for HPV+ head and neck cancer. WH Ireland analysts say PDS is making excellent progress in Phase-II programmes, citing a 21-month median survival versus three to four months with standard of care. They see a registration study as a potential value crystalliser.ProactiveinvestorsNetScientific adds 20% following promising results emerging from portfolio company PDSNetScientific shares rose 20% on Friday, bringing weekly returns above 30%, after portfolio company PDS Biotechnology announced preclinical data showing its Infectimune platform generates a broad immune response against SARS-CoV-2 and influenza. The results were published in the peer-reviewed journal Viruses.ProactiveinvestorsNetScientific confirms John Clarkson steps down in line with careful planning to recruit new chairmanJohn Clarkson stepped down as chairman of NetScientific PLC and resigned from the board immediately. Jonathan Robinson will serve as interim non-executive chairman while the company completes its search for a new chairman, with interviews scheduled shortly.ProactiveinvestorsNetscientic notes portfolio company PDS Biotechnology's latest trial reports in advanced cancer patientsPDS Biotechnology reported expanded interim data from a Phase 2 trial of its PDS0101-based triple combination therapy in advanced HPV-positive cancers. Among 50 evaluable patients, median overall survival was 21 months in checkpoint inhibitor-refractory patients, with 63% and 88% objective response rates in refractory and naïve groups, respectively.ProactiveinvestorsNetScientific climbs as PDS Biotech cancer trial logs 100% responsePDS Biotech reported that all nine patients in its Phase 2 cervical cancer trial responded to PDS0101 plus CRT, with eight achieving complete response by day 170. The company also presented expanded interim data from a triple-combination trial showing 66% survival. NetScientific shares rose 9% to 65p, while PDS shares climbed 27% to US$7.12.ProactiveinvestorsNetScientific highlights progress of PDS Biotech cancer treatmentPDS Biotech presented clinical data from two Phase 2 trials of its HPV-positive cancer treatment PDS0101 at the Society for Immunotherapy of Cancer meeting in November 2022. The data suggest PDS0101 can elicit a therapeutic immune response and may work with other agents to exceed current standards of care.ProactiveinvestorsNetScientific subsidiary takes stake in heat pump system makerNetScientific subsidiary EMV Capital led a £2.5m investment round in heat pump maker Ventive, taking a roughly 16% equity stake. The deal includes £600k in equity and debt, restructuring £1m of Ventive's historical debt and releasing a £1.5m UK business grant. Ventive partners with QM Systems to scale production.ProactiveinvestorsNetScientific portfolio opportunities are “significantly undervalued”, says brokerPDS Biotechnology, in which NetScientific holds a 4.72% stake, announced expanded interim data from a Phase II study of its lead candidate PDS0101 with Merck drugs in advanced HPV+ cancers. WH Ireland analysts say the market undervalues the opportunity, valuing NetScientific's stake at 59.9p per share versus a 200p SOTP fair value.